¸®¼ÒÁ» ÃàÀû Áúȯ Ä¡·áÁ¦ ½ÃÀå : Ä¡·áÁ¦, ÀûÀÀÁõ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ½ÃÀå ±Ô¸ð, Á¡À¯À², Àü¸Á ¹× ±âȸ ºÐ¼®(2023-2030³â)
Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy ), By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
»óǰÄÚµå : 1304410
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,197,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,640,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®¼ÒÁ» ÃàÀû Áúȯ(LSD)Àº ´ÜÀÏ À¯ÀüÀÚ °áÇÔÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â Áúº´ÀÔ´Ï´Ù. È¿¼Ò °áÇÔÀº LSDÀÇ °ÅÀÇ 70%¸¦ À¯¹ßÇÏ°í ³ª¸ÓÁö´Â È¿¼Ò Ȱ¼ºÈ­ ÀÎÀÚ ¶Ç´Â °ü·Ã ´Ü¹éÁúÀÇ °áÇÔÀÔ´Ï´Ù. ƯÁ¤ ¿°»öü À¯ÀüÀÚÁ¿¡ ÀÖ´Â À¯ÀüÀڴ ƯÁ¤ È¿¼Ò¸¦ Àü»çÇÏÁö¸¸, È¿¼Ò Äڵ尡 ºÎÀûÀýÇÏ°Ô ÄÚµùµÇ¸é È¿¼Ò°¡ ºñȰ¼º »óŰ¡ µË´Ï´Ù. ¸¶Âù°¡Áö·Î, Ȱ¼ºÈ­ ÀÎÀÚÀÇ °áÇÔÀº Ȱ¼ºÈ­ ÀÎÀÚ À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º´¸®ÇÐÀº ±×µéÀÌ ÃàÀûµÇ´Â Àå±âÀÇ Áúº´À» À¯¹ßÇϰí ÀÓ»ó Áõ»ó°ú ¡Èĸ¦ °áÁ¤ÇÕ´Ï´Ù. ¿µÀ¯¾Æ¿Í ¾î¸°ÀÌ´Â ¼ºÀο¡ ºñÇØ ´õ ½É°¢ÇÕ´Ï´Ù. °°Àº Áúº´ÀÌ¶óµµ ¸¹Àº ¾î¸°ÀÌ¿Í ¼ºÀÎÀº ÀÓ»ó Áõ»óÀÌ ´Ù¸¨´Ï´Ù. ¿¹¸¦ µé¾î, ¹ß´ÞÁßÀÎ ¾î¸°ÀÌÀÇ ³ú´Â ¼Õ»óµÇ±â ½±°í ±â´É Àå¾ÖÀÇ Áõ»ó°ú ¡Èİ¡ ³ªÅ¸³ª±â ½±Áö¸¸ ¼ºÀÎÀÇ °æ¿ì °æ¹ÌÇϰųª ±×·¸Áö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î È¿¼Ò °Ë»ç°¡ ù ¹øÂ° Áø´Ü °Ë»çÀ̸ç, À¯ÀüÀÚ µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ À¯ÀüÀÚ ºÐ¼®ÀÌ Á¤¹Ðµµ¸¦ ³ôÀÔ´Ï´Ù. ÀÌ Áúȯ¿¡ ´ëÇÑ ÃֽŠġ·á¹ýÀÌ ¸¹ÀÌ ÀÖ½À´Ï´Ù. Àå±â Àå¾Ö°¡ ¹ß»ýÇϱâ Àü¿¡ Á¶±â¿¡ Ä¡·áÇϸé Àå¾Ö¸¦ ¿¹¹æÇϰųª Áö¿¬½ÃÄÑ »îÀÇ ÁúÀ» °³¼±ÇÏ°í ¼ö¸íÀ» ¿¬ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¸®¼ÒÁ» ÃàÀû ÁúȯÀÇ Á߿伺 Áõ°¡, °¢±¹ Á¤ºÎÀÇ ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ ½ÃÇà, ½ÅÁ¦Ç° Ãâ½Ã µîÀÌ ¼¼°è ¸®¼ÒÁ» ÃàÀû Áúȯ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù 11ÀÏ ¹Ì±¹ Á¦¾àȸ»ç Chiesi USA, Inc.´Â ÀÚ»çÀÇ Á¦Ç° Elfabrio°¡ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¾àÀº È¿¼Ò ´ëü ¿ä¹ý(ERT)¿¡ È¿¼Ò Æä±¸´Ï°¥½Ã´Ù¾ÆÁ¦ ¾ËÆÄ(pegunigalsidase alfa)¸¦ »ç¿ëÇÏ¿© ÆÄºê¸®º´ÀÌ È®ÀÎµÈ ¼ºÀΠȯÀÚ¸¦ Ä¡·áÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå »óȲ °³¿ä

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¸®¼ÒÁ» ÃàÀûÁúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¸®¼ÒÁ» ÃàÀûÁúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå : Ä¡·áÁ¦º°, 2018³â-2030³â

Á¦6Àå ¸®¼ÒÁ» ÃàÀûÁúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå : ÀûÀÀÁõº°, 2018³â-2030³â

Á¦7Àå ¸®¼ÒÁ» ÃàÀûÁúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018³â-2030³â

Á¦8Àå ¸®¼ÒÁ» ÃàÀûÁúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå : Áö¿ªº°, 2018-2030³â

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¼½¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Lysosomal storage diseases (LSDs) are diseases caused by defects in single-genes. Enzyme defects cause nearly seventy percent of the LSDs, and the rest are defects in enzyme activator or associated proteins. A gene on a particular chromosome locus transcribes a particular enzyme, improper enzyme-coding results in inactive enzymes. Similarly, defective activators result from mutations in activator genes. These conditions cause disease of the organs in which they accumulate and decide the clinical signs and symptoms. Infants and children suffer more severely compared to adults. The clinical features are unique in many children and adults for the same disease. For example, the child's developing brain is more susceptible to insults and manifests symptoms and signs of dysfunction, while this may be milder or absent in adults. Enzyme testing is usually the initial diagnostic test, but genetic analysis of the gene mutations adds precision. There are many modern therapeutic techniques for these conditions. When applied early before organ damage sets in, these therapies have the potential to prevent or delay damage, improve quality of life, and increase lifespan.

Market Dynamics

Increasing significance of lysosomal storage diseases, arrangement of awareness programs by governments and the launch of new products are attributed to the growth of the global lysosomal storage diseases therapeutics market. For instance, on May 11, 2023, Chiesi USA, Inc., a U.S. based pharmaceutical company announced that its product Elfabrio was approved by U.S. Food and Drug Administration. It uses the enzyme pegunigalsidase alfa for enzyme replacement therapy (ERT) to treat adults with confirmed Fabry disease.

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Lysosomal Storage Diseases Therapeutics Market- COVID-19 Impact Analysis

5. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)

6. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2018-2030, (US$ Billion)

7. Global Lysosomal Storage Diseases Therapeutics Market, By End user, 2018-2030, (US$ Billion)

8. Global Lysosomal Storage Diseases Therapeutics Market, By Region, 2018-2030, (US$ Billion)

9. Competitive Landscape

10. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â